NLX P101

Drug Profile

NLX P101

Alternative Names: GAD gene therapy; Glutamic acid decarboxylase gene therapy; STN AAV-GAD gene therapy

Latest Information Update: 06 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cornell University; Neurologix
  • Developer Neurologix
  • Class Antiparkinsonians; Gene therapies
  • Mechanism of Action GABA modulators; Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 22 Apr 2013 Diamyd Medical is now called Mertiva
  • 16 Mar 2012 Discontinued - Phase-II for Parkinson's disease in USA (Intracerebral)
  • 20 Feb 2012 Neurologix terminates long term trial in Parkinson's disease in USA (NCT01301573)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top